Thrombotic microangiopathy purpura in a patient with metastatic colorectal carcinoma
Abstract
Abstract
Background: Thrombotic microangiopathy (TMA) is a rare syndrome that leads to excessive formation of blood clots, microthrombosis and is accompanied by non-autoimune haemolytic anemia and thrombocytopenia. Only few cases describing TMA caused by cancer are being reported in the literature.
Patient: A 42-year old male patient with metastatic carcinoma of sigma and several accompanying diagnoses (pulmonary embolism, deep vein thrombosis, cerebrovascular insult) had later developed clinical and laboratory signs of TMA. TMA was unresponsive to plasmapheresis, which was discontinued and first cycle of chemotherapy was applied. The patient died soon after. The autopsy did not provide any additional information about the disease, there were no signs of malignant bone marrow infiltration.
Conclusion: The diagnosis of secondary TMA remains a diagnostic and therapeutic challenge. It appears as a rare complication in patients with cancer. Treatment is difficult because the cause of TMA (malignancy) is hard to remove. Patients with cancer do not respond to plasmapheresis, which often delays the application of chemotherapy, the only effective treatment for TMA. Consequently this condition has poor prognosis.
Downloads
References
Chemnitz J, Schulz A, Diehl V, Söhngen D. Thrombotic-thrombocytopenic purpura (Moschcowitz syndrome). Med Klin (Munich) 2001; 96: 343-50.
Sever M. Zdravljenje trombotične trombocitopenične purpure – naše izkušnje. ZV 2008; 77: 105-9.
Spoormans I, Altrintas S, Van den Brande J, Luijks A, Vermorken JB. Purpura in a patient with disseminated breast cancer: a rapidly progressive cancer-related thrombotic thrombocytopoenic purpura. Ann Oncol 2008; 19: 1204–7.
Scully M, Hunt BJ, Benjamin S, Liesner R, Rose P, Peyvand F, et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. BJH 2012; 158: 323-335.
Pirrotta MT, Bucalossi A, Forconi F, Bocchia M, Mazzootta S, Sammassimo S, et al. Thrombotic Thrombocytopoenic Purpura Secondary to an Occult Adenocarcinoma. The Oncologist 2005; 10: 299-300.
Sekhon SS, Roy V. Thrombocytopenia in Adults: A Practical Approach to Evaluation and Management Sudhir S. SMJ 2006; 99: 491-8.
Chang JC, Naqvi T. Thrombotic thrombocytopoenic purpura associated with bone marrow metastasis and secondary myelofibrosis in cancer. Oncologist 2003; 8: 375-80.
Kwaan HC, Gordon LI. Thrombotic microangiopathy in the cancer patient. Acta Haematologica 2001; 106: 52–56.
Glaser M. Pojav trombotične trombocitopenične purpure pri bolniku s karcinomom. ZV 2002; 71: 433-5.
Zver S, Noč M, Horvat M, Ponikvar R. Trombotična trombocitopenična purpura - prikaz kliničnega primera = Thrombotic thrombocytopenic purpura with case report. ZV 1997; 66: 187-9.
Francis KK, Kalyanam N, Terrell DR, Vesely SK, George JN. Disseminated Malignancy Misdiagnosed as Thrombotic Thrombocytopenic Purpura: A Report of 10 Patients and a Systemic Review of Published Cases. The Oncologist 2007; 12:11-19.
Oberic L, Buffeta M, Schwarzingerb M, Veyradierc A, Clabaultd K, Malota S, et al. Cancer Awareness in Atypical Thrombotic Microangiopathies. Oncologist 2009; 14: 769-79.
Pineda A, Vamvakas EC. Applications of Therapeutic Apheresis in Patients with Malignant Disease. Oncologist 1997; 2: 94-103.
Siniscalchi A, Stasi R, fratoni S, de Fabritiis P, Caravita T. Management of immune thromocytopoenia in a patient with newly-diagnosed smouldering myeloma and colorectal cancer. BMJ Case Reports 2009; doi: 10.1136/bcr.03.2009.1715.
Farhat MH, Souze B, Hanbali A. Cancer-related TTP: Role of plasma exchange. J Clin Onco 2009; 27: e13527.
Sisik A, Kaya M, Bas G, Basak F, Alimoglu O. CEA and CA 19-9 are Still Valuable Markers for the Prognosis of Colorectal and Gastric Cancer Patients . Asian Pac J Cancer Prev 2013; 14: 4289-94.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
